UWCCC Imaging and Radiation Sciences (IR) Program Summary Co-Leaders: Mark Ritter and Robert Jeraj PROJECT SUMMARY/ABSTRACT The Imaging and Radiation Sciences (IR) Program pursues basic, translational, and clinical research involving ionizing and non-ionizing radiation in the diagnosis, staging, and treatment of cancer. Our scope is integrated around 3 connected thematic aims: 1) To develop and translate innovative molecular imaging agents and imaging technologies to improve cancer detection and treatment; 2) To develop molecular, immunological, radiobiological and technological approaches that improve radiation treatment response; and 3) To advance synergies between imaging and radiation sciences for more effective personalization of localized therapies. Notable achievements since the last CCSG renewal include advancement of the theranostic agent CLR1404 into clinical trials, development of IR Program-led cooperative group trials using FLT PET in AML, and incorporating EGFR targeting in treatment of head and neck cancer. Several novel molecular imaging and treatment agents (e.g., 64Cu-NOTA-YY146), several novel imaging technologies (e.g., US-based elastography imaging of breast cancer), and several novel image analysis methods (e.g., Quantitative Total Bone Imaging) have been developed enabling better diagnosis, targeting, and understanding of treatment response in several cancers. The IR program has defined the mechanisms of HPV infection related radiosensitivity, has identified new radiation ? immunotherapy interactions with a therapeutic potential and has leveraged large fraction radiobiology in multiple clinical trials. In 2013, IR established the Wisconsin Oncology Network for Imaging Excellence (WONIX), a program aimed at bringing advanced, research grade imaging technology and imaging- based clinical trials to other medical centers across Wisconsin. In 2016, the IR Program was awarded the first UWCCC SPORE in Head and Neck cancer. Finally, and critically, both cooperative group and investigator initiated trial accrual has markedly increased relative to accrual at the time of the last CCSG renewal. These are strong results of a collaborative Program including: 33 members from 7 departments have a total of about $5 M in peer-reviewed, annual direct costs in 2016 (>42%, $2.11 M from NCI). These research efforts have led to 642 peer-reviewed publications since 2012, with intra-programmatic publications increasing from 13.0% in 2012 to 19.7% in 2016 and inter-programmatic increasing from 7.0% to 13.6% over the same period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-45
Application #
9706775
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Shea, Michael P; O'Leary, Kathleen A; Wegner, Kyle A et al. (2018) High collagen density augments mTOR-dependent cancer stem cells in ER?+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Lett 433:1-9
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150
Yu, Bo; Wei, Hao; He, Qianjun et al. (2018) Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 57:218-222
Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei et al. (2018) Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 45:123-131
Ferreira, Carolina A; Hernandez, Reinier; Yang, Yunan et al. (2018) ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm 15:3434-3441
Conklin, Matthew W; Gangnon, Ronald E; Sprague, Brian L et al. (2018) Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev 27:138-145
Ko, Huaising C; Kimple, Randall J (2018) The Resident Individual Development Plan as a Guide for Radiation Oncology Mentorship. Int J Radiat Oncol Biol Phys 101:786-788
McDermott, Andrew J; Tumey, Tyler A; Huang, Mingwei et al. (2018) Inhaled Cryptococcus neoformans elicits allergic airway inflammation independent of Nuclear Factor Kappa B signalling in lung epithelial cells. Immunology 153:513-522
You, Xiaona; Kong, Guangyao; Ranheim, Erik A et al. (2018) Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood 132:2575-2579

Showing the most recent 10 out of 1528 publications